Expression of protease-activated receptor-1 and-2 in orofacial granulomatosis

被引:6
|
作者
Ketabchi, S.
Massi, D.
Ficarra, G.
Rubino, I.
Franchi, A.
Paglierani, M.
Simoni, A.
Capodiferro, S.
Favia, G.
Maiorano, E.
Tarantini, F.
Cirino, G.
Santucci, M.
机构
[1] Univ Florence, Dept Human Pathol & Oncol, I-50121 Florence, Italy
[2] Univ Florence, Dept Ofontostomatol, Reference Ctr Study Oral Dis, I-50121 Florence, Italy
[3] Univ Bari, Dept Dent & Surg, I-70121 Bari, Italy
[4] Univ Bari, Dept Pathol Anat, I-70121 Bari, Italy
[5] Univ Florence, Dept Crit Care Med & Surg, I-50121 Florence, Italy
[6] Univ Naples Federico 2, Dept Expt Pharmacol, I-80138 Naples, Italy
关键词
orofacial granulomatosis; PAR-1; PAR-2; MMP-2; MMP-9; COX-1; COX-2; immunohistochemistry; MELKERSSON-ROSENTHAL SYNDROME; CROHNS-DISEASE; MATRIX METALLOPROTEINASES; MANAGEMENT; INVASION;
D O I
10.1111/j.1601-0825.2006.01317.x
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objective: Orofacial granulomatosis (OFG) is a rare condition characterized by non-caseating granulomas in the orofacial region. Protease-Activated Receptors (PARs) play a role in inflammatory diseases in diverse human tissues. The aim of the study was to investigate the expression of PAR-1, PAR-2, MMP-2, MMIP-9, COX-1, and COX-2 in tissues taken from OFG patients. Methods: PAR-1, PAR-2, MMP-2, MMP-9, COX-1, and COX-2 expression was evaluated by immunohistochemistry in biopsies taken from oral Crohn's disease (five cases), Melkersson-Rosenthal syndrome (MRS) (six cases), cheilitis granulomatosa (five cases) and normal oral mucosa (five cases). Results: PAR-1 was observed in mononuclear inflammatory cells in edematous/lichenoid lesions, whereas a strong PAR-2 immunostaining was detected in epithelioid histiocytes and giant cells in granulomatous lesions, irrespective of the clinical features (Crohn vs MRS). MMPs and COX-2 were expressed in the inflammatory component of edematous/lichenoid lesions and markedly overexpressed in granulomatous lesions. COX-1 was weakly and variably expressed in both edematous/ lichenoid and granulomatous lesions. Conclusion: Thus, PAR-I and PAR-2 expressions were related to the intensity and type of inflammatory response but not to the type of clinical lesion. Simultaneous overexpression of PARs, MMPs and COXs suggests synergism among these proinflammatory receptors and enzymes.
引用
收藏
页码:419 / 425
页数:7
相关论文
共 50 条
  • [1] Regulation of protease-activated receptor-1 and-2 expression on antigen presenting cells by cytokines
    Colognato, R
    Slupsky, JR
    Jendrach, M
    Burysek, L
    Simmet, T
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2001, 363 (04) : R82 - R82
  • [2] Analysis of protease-activated receptor-1 and-2 in human scar formation
    Materazzi, S.
    Pellerito, S.
    Di Serio, C.
    Paglierani, M.
    Naldini, A.
    Ardinghi, C.
    Carraro, F.
    Geppetti, P.
    Grino, G.
    Santucci, M.
    Tarantini, F.
    Massi, D.
    JOURNAL OF PATHOLOGY, 2007, 212 (04): : 440 - 449
  • [3] The effects of stimulating protease-activated receptor-1 and-2 in A172 human glioblastoma
    Okamoto, T
    Nishibori, M
    Sawada, K
    Iwagaki, H
    Nakaya, N
    Jikuhara, A
    Tanaka, N
    Saeki, K
    JOURNAL OF NEURAL TRANSMISSION, 2001, 108 (02) : 125 - 140
  • [4] Protease-activated receptor-1 at the synapse
    Shavit-Stein, E.
    Katzev, A.
    Chapman, J.
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2011, 45 (SUPPL 1) : S108 - S108
  • [5] Role of Protease-Activated Receptor-1 in Glioma Growth
    Xie, Qing
    Bao, Xuhui
    Chen, Zhan Hong
    Xu, Ying
    Keep, Richard F.
    Muraszko, Karin M.
    Xi, Guohua
    Hua, Ya
    BRAIN EDEMA XVI: TRANSLATE BASIC SCIENCE INTO CLINICAL PRACTICE, 2016, 121 : 355 - 360
  • [6] Vorapaxar: a novel protease-activated receptor-1 inhibitor
    Gurbel, Paul A.
    Jeong, Young-Hoon
    Tantry, Udaya S.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (10) : 1445 - 1453
  • [7] The role of protease-activated receptor-1 in bone healing
    Song, SJ
    Pagel, CN
    Campbell, TM
    Pike, RN
    Mackie, EJ
    AMERICAN JOURNAL OF PATHOLOGY, 2005, 166 (03): : 857 - 868
  • [8] Therapeutic potential of protease-activated receptor-1 antagonists
    Derian, CK
    Maryanoff, BE
    Zhang, HC
    Andrade-Gordon, P
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (02) : 209 - 221
  • [9] Protease-Activated Receptor-1 Signaling The Big Picture
    Flaumenhaft, Robert
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2017, 37 (10) : 1809 - 1811
  • [10] Granzyme K Activates Protease-Activated Receptor-1
    Cooper, Dawn M.
    Petchkovsky, Dmitri V.
    Hackett, Tillie L.
    Knight, Darryl A.
    Granville, David J.
    PLOS ONE, 2011, 6 (06):